Esperion Therapeutics, Inc. SEC Filings

Esperion Therapeutics Chief Financial Officer Sheldon L. Koenig reported a routine stock transaction involving company shares. On 12/17/2025, he sold 7,337 shares of Esperion Therapeutics common stock at a price of $3.667 per share. According to the filing, these shares were sold to cover tax obligations arising from the vesting of restricted stock units. After this sale, Koenig beneficially owned 467,525 shares of Esperion common stock, held directly.

Esperion Therapeutics, Inc. reported an insider stock transaction by its General Counsel. On 12/17/2025, the officer sold 6,517 shares of common stock at a price of $3.667 per share. According to the explanation, these shares were sold to satisfy tax obligations arising from vested restricted stock units, meaning the sale was related to tax withholding rather than a discretionary liquidation of holdings. Following this transaction, the reporting person directly owned 385,905 shares of Esperion common stock.

Esperion Therapeutics, Inc. filed an initial ownership report for a senior executive showing no equity holdings. The filing is a Form 3 for the company’s Chief Commercial Officer, who is classified as an officer of Esperion Therapeutics, Inc. (ticker ESPR). The event date for this ownership status is listed as 11/17/2025. According to the remarks, no securities of Esperion, either direct or derivative, are beneficially owned by this reporting person as of that date.

Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.

Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.

Esperion Therapeutics filed a Form 8-K stating it furnished a press release announcing financial results for the three and nine months ended September 30, 2025.

The information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act except as specifically referenced.

Esperion Therapeutics appointed John B. Harlow, Jr. as Chief Commercial Officer, effective November 17, 2025. The hire adds a veteran commercial leader with prior CCO roles at Melinta Therapeutics and Baudax Bio.

Under his agreement, Harlow will receive a $535,000 base salary, a target bonus equal to 45% of salary, and a $35,000 sign-on bonus. Equity awards include options for 380,000 shares at the grant-date closing price and 424,536 RSUs, each vesting over four years, subject to continued service. Severance provides one year of salary (and, upon a sale event, salary plus target bonus) and COBRA-related cash payments, subject to customary release conditions.

Esperion Therapeutics (ESPR) reported an insider transaction by its General Counsel. On 10/17/2025, the officer sold 1,248 shares of common stock at $2.6245 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units.

Following the sale, the officer directly owned 392,422 shares. This Form 4 reflects a tax-related sale rather than an open-market disposition for investment purposes.

Esperion Therapeutics, Inc. filed an 8-K reporting a material event that centers on a securities offering. The filing references two press releases dated October 7, 2025: one announcing the offering and one announcing the pricing of the offering. The company also disclosed an opinion of Goodwin Procter LLP and the firm's consent (included as Exhibit 5.1). The document includes the interactive data cover page and is signed by Sheldon Koenig, President and Chief Executive Officer on October 8, 2025. The filing shows the offering has been publicly announced and legally documented, but it does not disclose offering size, securities type, or net proceeds.

Esperion Therapeutics, Inc. is offering 30,000,000 shares of common stock at a public offering price of $2.50 per share, with an underwriter option for an additional 4,500,000 shares. Estimated net proceeds are approximately $70.2M (or $80.7M if option exercised). The company plans to use proceeds to fund commercialization of NEXLETOL and NEXLIZET, R&D, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s that delays generic entry for NEXLETOL and NEXLIZET in the U.S. until April 19, 2040, and regulatory progress with approvals and filings in Japan, Canada, Israel and Australia with expected national pricing/approvals in late 2025 to 2026. The offering will dilute new investors; pro forma net tangible book value remains negative at $(1.56) per share after the offering, producing an immediate dilution of $4.06 per share to new investors.